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The origins of the major classes of current anti-emetics are examined. Serendipity is
a recurrent theme in discovery of their anti-emetic properties and repurposing from
one indication to another is a continuing trend. Notably, the discoveries have occurred
against a background of company mergers and changing anti-emetic requirements.
Major drug classes include: (i)Muscarinic receptor antagonists–originated from historical
accounts of plant extracts containing atropine and hyoscine with development stimulated
by the need to prevent sea-sickness among soldiers during beach landings; (ii) Histamine
receptor antagonists–searching for replacements for the anti-malaria drug quinine,
in short supply because of wartime shipping blockade, facilitated the discovery of
histamine (H1) antagonists (e.g., dimenhydrinate), followed by serendipitous discovery
of anti-emetic activity against motion sickness in a patient undergoing treatment for
urticaria; (iii) Phenothiazines and dopamine receptor antagonists–investigations of their
pharmacology as “sedatives” (e.g., chlorpromazine) implicated dopamine receptors in
emesis, leading to development of selective dopamine (D2) receptor antagonists (e.g.,
domperidone with poor ability to penetrate the blood-brain barrier) as anti-emetics in
chemotherapy and surgery; (iv) Metoclopramide and selective 5-hydroxytryptamine3
(5-HT3) receptor antagonists–metoclopramide was initially assumed to act only
via D2 receptor antagonism but subsequently its gastric motility stimulant effect
(proposed to contribute to the anti-emetic action) was shown to be due to
5-hydroxytryptamine4 receptor agonism. Pre-clinical studies showed that anti-emetic
efficacy against the newly-introduced, highly emetic, chemotherapeutic agent cisplatin
was due to antagonism at 5-HT3 receptors. The latter led to identification of selective
5-HT3 receptor antagonists (e.g., granisetron), a major breakthrough in treatment of
chemotherapy-induced emesis; (v) Neurokinin1 receptor antagonists–antagonists of the
actions of substance P were developed as analgesics but pre-clinical studies identified
broad-spectrum anti-emetic effects; clinical studies showed particular efficacy in the
delayed phase of chemotherapy-induced emesis. Finally, the repurposing of different
drugs for treatment of nausea and vomiting is examined, particularly during palliative
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care, and also the challenges in identifying novel anti-emetic drugs, particularly for
treatment of nausea as compared to vomiting. We consider the lessons from the past
for the future and ask why there has not been a major breakthrough in the last 20 years.
Keywords: nausea and vomiting, drug discovery, metoclopramide, histamine H1 receptor antagonists, muscarinic
receptor antagonists, 5-hydroxytryptamine3 receptor antagonists, neurokinin1 receptor antagonists, olanzapine
INTRODUCTION
The sensation of nausea and the ability to vomit are key
components of human defenses against unintentional ingestion
of noxious material and are part of a hierarchically organized
defensive system (Figure 1; Davis et al., 1986; Stern et al., 2011).
Ingested toxins must be detected rapidly and reliably, nausea
induced quickly to limit further ingestion, and vomiting initiated
promptly to void contaminated ingested material whilst still in
the lumen of the upper digestive tract.
Nausea is considered a “warning.” It can be considered to
represent “low intensity” stimulation of afferent pathways, which
if activated more intensely, trigger vomiting, yet paradoxically,
it is considered easier to prevent vomiting rather than nausea
by anti-emetic drugs (Andrews and Sanger, 2014). Likewise, risk
factors for induction of nausea as opposed to vomiting may
also differ, as exemplified by post-operative nausea and vomiting
(Stadler et al., 2003). An accepted function of nausea is that it
FIGURE 1 | A summary of the levels of defense employed to initially avoid and, if required, to detect and respond to toxins ingested with the food. AP, area postrema
(also known as the “chemoreceptor trigger zone” for emesis, but see text for discussion); NTS, nucleus tractus solitarius; the site in the dorsal brainstem where inputs
from the vagal afferents and the area postrema are integrated and from which outputs pass to other areas of the brainstem to coordinate the motor outputs for
vomiting and from which information is relayed to “higher” brain regions to evoke the sensation of nausea. Figure adapted and modified from Andrews (1993).
causes a learned aversion to the food associated with the nausea,
leading to avoidance when subsequently encountered, sometimes
lifelong (Stern et al., 2011).
The pathways which evolved to detect ingested toxins and
aberrant motion can also be triggered by diverse diseases
and pharmacological therapies (Figure 2). Thus, nausea and
vomiting rather than being adaptive responses of evolutionary
significance (arguably including pregnancy sickness in humans;
Profet, 1988, 1992; Flaxman and Sherman, 2000 but for a
different view see Brown et al., 1997; Weigel et al., 2006)
become “symptoms of disease” or “side-effects of drugs” which
often require treatment (Figure 2). Motion sickness, pregnancy
sickness and adverse effects of therapy (primarily for cancer)
have driven the development of anti-emetic drugs since the early
1940s.
Anti-emetics are sometimes viewed as a niche therapeutic area
but this is incorrect as: (a) Nausea and vomiting are amongst
the most common reasons for an emergency department visit
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FIGURE 2 | Diagram illustrating that nausea and vomiting can be evoked by stimuli ranging from toxins in the food where they may be viewed as an “appropriate”
response helping to defend the animal, to diseases and therapeutic interventions where they are viewed as undesirable and are classified as “symptoms” or
“side-effects.” Profile of the head from http://getdrawings.com/talking-head-silhouette.
(Meek et al., 2015), (b) An anti-emetic (ondansetron) was on
the list of drugs with sales of one billion $US a year before
patent expiry and together with metoclopramide (an anti-emetic
and gastric prokinetic drug), ondansetron has been included
on the World Health Organization list of essential medicines1,
(c) Developments in anti-emetics (particularly antagonists at
5-hydroxytryptamine3 receptors; 5-HT3) were included in the
“top five advances” in modern oncology in a 2014 American
Society for Clinical Oncology survey2, (d) Anti-emetics decrease
overall healthcare costs in cancer patients because they enable
treatment in day centers and reduce the need for hospitalization
following severe vomiting; a similar argument applies to post-
operative nausea and vomiting (PONV), reducing the need for
longer (particularly overnight) hospitalization, (e) Anti-emetics
provide rare examples of clinical agents acting as an antagonist at
a ligand-gated ion channel (5-HT3) and at a receptor for a peptide
(neurokinin1; NK1), (f) Significant conditions remain in which
nausea represents a defining but poorly-treated symptom in large
patient populations (e.g., palliative care, gastroparesis, functional
dyspepsia).
1https://web.archive.org/web/20161213052708/http://www.who.int/medicines/
publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?
ua=1
2https://www.asco.org/about-asco/press-center/news-releases/asco-50th-
anniversary-poll-names-top-5-advances-past-50-years
In this review, current nomenclature is used3 to describe
G-Protein Coupled Receptors (GPCRs) and ion channels.
Nevertheless, it is important to appreciate that when many
anti-emetic drugs were discovered, their target GPCR or ion
channel was not fully characterized or even defined. Progress
in understanding anti-emetic drug physiology and receptor
pharmacology can therefore be viewed as running in parallel with
characterization of these targets. Such progress also illustrates
the evolution in methods of drug discovery, from early reliance
on animals to define therapeutic and adverse effects of drug
candidates, through to the use of such models to define novel
receptor functions (e.g., 5-HT3 receptor) and today’s focus on
recombinant human receptors to characterize compound activity
before translation using animals and humans. The last 30 years
in particular, have also seen major re-organizations of the
pharmaceutical industry. Figure 3 shows the companies which
played significant roles in anti-emetic drug discovery, many
of which disappeared during mergers and takeovers, impacting
research. Table 1 provides details of key contributions.
This review outlines the mechanisms of nausea and vomiting,
providing a background to the discovery and pharmacology
of licensed anti-emetic drugs and compounds still in clinical
development. We examine the shifting strategies adopted by
the pharmaceutical industry and academia over the last ∼75
3http://www.guidetopharmacology.org/
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FIGURE 3 | Major players in the pharmaceutical industry responsible for the development of the main anti-emetic drugs over the time course covered by this review.
See text for details and references.
years. Lessons learned and challenges to further advances are also
highlighted, together with current research trends.
COMMON CAUSES OF NAUSEA AND
VOMITING
The three main causes of nausea and vomiting whichmay require
therapeutic intervention are diseases (organic and functional),
drug or other therapies (e.g., PONV) and motion sickness.
Amongst the diseases, digestive tract disorders are currently
being investigated most actively, with interest focused on the
genesis of nausea in conditions such as gastroparesis (see
below). Treatment of the emetic side effects of anti-cancer
chemotherapy (Andrews and Rudd, 2016), analgesics in palliative
care (Smith and Laufer, 2014) and PONV (Horn et al., 2014)
are the commonest examples in the “side-effect of therapy”
category (for reviews see Stern et al., 2011; Koch and Hasler,
2017) but it should also be noted that nausea and vomiting
are surprisingly common side-effects of drugs in general; the
Electronic Medicines Compendium indicates nausea as an
adverse event for>50% of a wide range of drugs and both nausea
and vomiting for >33% (Lee, 2006). Indeed, as an adverse event,
nausea and vomiting is second only to the potential for abuse
liability in their impact on development of new chemical entities
(NCEs) as therapeutic agents (Holmes et al., 2009), so predicting
such liability early in the discovery process is of high importance.
Meta-analysis and database mining of “historic” animal and
human studies (which may never be repeated) provide a useful
approach to identification of chemical templates most likely to
induce vomiting (Parkinson et al., 2012; Percie du Sert et al.,
2012).
Motion sickness is not a disease but, apart from food
poisoning and pregnancy, it is probably the most likely cause
of nausea and vomiting experienced by readers of this review.
Medications used for travel sickness (e.g., Joy Ridesr and
Kwellsr [formulations of hyoscine hydrobromide]; Stugeronr
[cinnarizine]) are rare examples (in the UK) of widely-used
anti-emetics available without prescription. Interest in motion
sickness continues because of “space motion sickness,” occurring
in∼70% of astronauts during the first 3 days in space (Crampton,
1990; Weerts et al., 2015).
CLINICAL NEED FOR ANTI-EMETIC
DRUGS
Vomiting has a diverse range of potential impacts upon the
person involved and also potentially on others. The consequences
are psychological (e.g., demeaning), physical (e.g., chronic fatigue
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TABLE 1 | The major pharmaceutical companies involved in the discovery of anti-emetic drugs during the period covered by this review and a summary of their key
contribution to the area.
Rhône-Poulenc Laboratories
• Rapidly focussed on the therapeutic potential of the newly-discovered “antihistamines,” searching libraries of compounds originally synthesized for another use. The first
antihistamine to treat anaphylaxis and allergic reactions was phenbenzamine, introduced into the clinic in 1942.
• Re-examination of the antihistamines to optimize the “anti-shock” property led to synthesis in 1946 of chlorpromazine (4560-R.P). This compound had low
antihistamine activity but in 1951 the company demonstrated its ability to prevent emesis evoked by apomorphine in dogs.
G.D. Searle & Co
• Introduced the “antihistamine” dimenhydrinate (Dramamine), a combination of diphenhydramine and 8-chlorotheophylline (a mild stimulant and derivative of
theophylline) as a counter measure against the drowsiness, somnolence, and sedation caused by H1 receptor antagonism within the brain.
Burroughs Wellcome
• Developed the “antihistamine” cyclizine, in 1947, subsequently taken on the Apollo moon missions as a treatment for space sickness.
Laboratoires Delagrange
• Identified metoclopramide in the mid-1950s, during a programme aimed at improving the properties of procainamide, a cardiac anti-arrhythmic and local anesthetic
drug derived from procaine. The drug had negligible local anesthetic or cardiac anti-arrhythmic activity but an ability to inhibit emesis in dogs evoked by multiple stimuli.
Soon after, metoclopramide was also found to stimulate GI motility and reduce symptoms associated with various upper GI disorders.
Janssen Pharmaceutica
• Among the antipsychotic compounds the company had developed in the mid-1950s, some were effective antagonists at the dopamine receptors in the chemoreceptor
trigger zone, an area of brain outside the blood-brain barrier, involved in regulation of vomiting. Domperidone was identified in 1974 as an antagonist which did not
cross the blood-brain barrier and hence, less likely to evoke the extrapyramidal side-effects.
Merrell Dow
• Synthesized MDL72222 from the chemical template of cocaine, the first selective 5-HT3 receptor antagonist, originally aimed at the treatment of migraine. A later
compound (MDL73147 or dolasetron) was marketed for the control for chemo-radiotherapy-induced emesis.
Beecham Pharmaceuticals
• Identified the anti-emetic activity of the 5-HT3 receptor antagonists, developing its own molecule (BRL43694 or granisetron, launched by SmithKline Beecham for the
control of chemoradiotherapy-induced emesis) and successfully filed a patent to cover the anti-emetic use of Glaxo’s compound (GR38032F or ondansetron), originally
designed for treatment of “a variety of disorders including migraine” before being specifically patented for treatment of depression, schizophrenia, anxiety, and cognitive
disorders.
Glaxo
• Identified ondansetron for the treatment of migraine and a variety of CNS disorders. Subsequent marketing as an anti-emetic drug incurred royalty payments to
Beecham/SmithKline Beecham who owned the patent covering the anti-emetic use of this drug.
Sandoz
• Identified the 5-HT3 receptor antagonist ICS 205-930 (tropisetron), originally for treatment of migraine, subsequently sponsoring research to characterize its anti-emetic
activity and “re-purpose” for treatment of chemoradiotherapy-induced emesis.
Merck
• Aprepitant introduced in 2003, following initial characterization for treatment of depression and emesis and a long history of failure of other NK1 receptor antagonists to
treat pain.
Syntex Discovery Research
• Synthesized and characterized palonosetron (RS 25259-197), licensed to Eisai and Helsinn for co-marketing in the USA in 2003 (the same year as aprepitant).
See text for further details.
and fractured ribs), metabolic (e.g., dehydration, anorexia) and
when caused by medications, can affect therapeutic outcomes
(e.g., if treatments are refused); these are summarized in Figure 4.
In circumstances when the vomiting is not induced by food-
borne toxins, blockade by an anti-emetic drug is desirable.
Notably, although vomiting is unpleasant, patients are frequently
more concerned about nausea, because as with chronic pain, it
can be unremitting. In contrast, vomiting occurs in episodes,
albeit sometimes spread over many days. Further, the adaptive
function of nausea (learning to avoid foods that caused its
induction on a previous encounter) becomes a liability when
it leads to avoidance and refusal of potentially curative therapy
in the case of some anti-cancer chemotherapy (Maceira et al.,
2012).
This review focuses on the identification of anti-emetic drugs
for therapeutic use in humans. Not discussed are important
veterinary applications, particularly in oncology (Kenward et al.,
2017).
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FIGURE 4 | A summary of the physical, physiological, and psychological consequences of nausea and vomiting for the person suffering, as well as for any observers
including health care professionals. The potential risk of infection from vomiting is also highlighted. Profile of the head from http://getdrawings.com/talking-head-
silhouette.
BRIEF INTRODUCTION TO MECHANISMS
The pathways involved both in the induction and the motor
outputs of emesis are briefly described, so the sites of action of
anti-emetics (discussed below) can be identified (Figure 5).
Major Pathways
Vestibular System
Although motion sickness can be induced by the vestibular
system alone (Irwin 1881; the first person to use the term “motion
sickness”), it more often involves conflicting or discordant signals
from the vestibular and visual systems, possibly with involvement
of proprioceptive inputs (Money, 1970; Reason, 1978; Oman,
2012; Lackner, 2014; Yates et al., 2014; Golding and Gresty, 2015;
Bertolini and Strauman, 2016).
Area Postrema (AP)
Located at the caudal extremity of the IVth ventricle, the area
postrema is characterized by relatively permeable blood-brain
and cerebrospinal fluid-brain barriers. Lesion studies primarily
in the 1950s and 1960s (e.g., Wang and Borison, 1952; for
review see Borison, 1989) implicated this region in the emetic
response to a diverse range of substances in the blood and led
to its description as the “chemoreceptor trigger zone” (CTZ)
for emesis. A widespread view then developed that agents in
the circulation could only induce emesis via the AP, resulting in
this region becoming a focal point for therapeutic intervention
(see Domperidone, below) and distracting attention from the
involvement of other pathways activated by systemic agents.
Nevertheless, the importance of the AP is exemplified by its
role in the induction of emesis by a number of endogenous
circulating agents (e.g., adrenaline, glucagon-like peptide-1,
cholecystokinin) as well as by drugs (e.g., apomorphine, digoxin,
morphine; see Stern et al., 2011). The reliable activation of
emesis by apomorphine via the AP led to its widespread
use as a test stimulus for investigating potential anti-emetic
agents but over-simplistic interpretation of the blockade of
apomorphine-induced emesis by candidate drugs may have led
to erroneous conclusions as illustrated by a quotation from
Borison and McCarthy (1983, p. 16): “A misconception of the
emetic mechanism that has led to false critical expectations is
the idea that experimental drug antagonism of apomorphine-
induced vomiting is equivalent to general inactivation of the
chemoreceptor trigger zone.”
Abdominal Vagal Afferents
Projecting from the stomach and small intestine, vagal afferent
neurons send information to the brain stem about themechanical
activity of the muscle and the chemical nature of the luminal
environment. This includes the effects of distension, particularly
of the gastric antrum and duodenum, which can induce nausea
and vomiting but paradoxically, gastric motor quiescence is
also associated with nausea (Sanger et al., 2013). Increasing
evidence also points toward dysrhythmic gastric movements in
certain conditions associated with nausea (e.g., gastroparesis)
thought to be detected by vagal mechanoreceptors and signaled
to the brainstem (Stern et al., 2011). In addition, the mucosal
chemoreceptive vagal afferents are implicated in emesis caused
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FIGURE 5 | Summary of the pathways responsible for the induction of nausea and vomiting (blue arrows), the integrative regions in the brain stem (blue box indicates
dorsal brain stem and nucleus tractus solitarius in particular) and the output pathways for nausea (green) and the motor outputs for vomiting (red box indicates the
pathways in the ventral brain stem). See text for details of pathways. CB1, cannabinoid1 receptor; D2, dopamine2 receptor; H1, histamine1 receptor; M3/5,
muscarinic3/5 acetylcholine receptor; 5-HT3-5-hydroxytryptamine3 receptor; 5-HT4-5-hydroxytryptamine4 receptor; NK1, tachykinin neurokinin 1 receptor. Adapted
and modified from Stern et al. (2011).
by ingested luminal toxins and irritants. In this setting, the
detection of substances in the lumen is via enteroendocrine cells
within the mucosa, which release neuroactive substances (e.g.,
5-HT, cholecystokinin) locally to activate receptors on the vagal
afferents terminating in close proximity. Based upon direct and
circumstantial evidence, Andrews et al. (1988) proposed that the
enteroendocrine cells and the vagal afferents were involved in the
acute emetic response to anti-cancer chemotherapeutic agents
(e.g., cisplatin, cyclophosphamide) and abdominal radiation by
the release of 5-HT (and other substances; see below) from the
cells to act at 5-HT3 receptors on the vagal afferent terminals (see
Andrews and Rudd, 2016 for review).
Motor Outputs
Vomiting
Vomiting is a reflex motor event coordinated in the brainstem.
Classically, the term “vomiting center” described the brainstem
locus from which vomiting could be induced when stimulated
and was viewed as a conceptual target for anti-emetic drugs
(Wang and Borison, 1950). Although “vomiting center” is a
useful concept and is still used in text books (e.g., Rang and Dale’s
Pharmacology; Ritter et al., 2016), as the network of brainstem
nuclei [e.g., nucleus tractus solitarius (NTS), dorsal motor vagal
nucleus, Bötzinger complex] responsible for the genesis and
coordination of the retching and vomiting motor pattern have
been identified (Hornby 2001), such “black box” descriptions of
networks may become redundant.
Key events in vomiting are: (a) Relaxation of the proximal
stomach via reciprocal changes in activity of vagal inhibitory and
excitatory neurons, together with a retrograde giant contraction
(RGC) beginning in the lower small intestine and progressing
to the stomach under vagal control (Lang, 2016). These changes
confine potentially-contaminated gastric content to the stomach
(the only place from which ejection by vomiting is possible)
and the RGC returns already-emptied contents to the stomach.
Retching only begins once the RGC reaches the stomach; (b)
Contraction of the hiatal region of the diaphragm and inhibition
of the crural diaphragm surrounding the lower esophagus by the
phrenic nerve, and contraction of the abdominal muscles by the
spinal motor neurons. It is these motor events which in terrestrial
mammals provide the propulsive force for oral ejection of gastric
contents (see Stern et al., 2011; Koch and Hasler, 2017).
Nausea
Compared with vomiting, nausea is poorly understood and
difficult to define operationally (Stern et al., 2011; Balaban and
Yates, 2017). There are, for example, fewer than 10 published
human brain imaging studies investigating brain activity during
nausea and all but one (Miller et al., 1996) used illusory self-
motion as the stimulus. These studies implicate the anterior
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cingulate cortex (“visceromotor cortex”), inferior frontal gyrus,
insular cortex and amygdala (Napadow et al., 2012; Farmer et al.,
2015; Sclocco et al., 2016). In some brain areas (e.g., posterior
cingulate cortex) the activity showed a negative correlation with
nausea (Farmer et al., 2015). However, it must be emphasized
that we do not yet know which regions are associated with the
genesis of nausea and which are associated with the emotional
and stressful aspects of the sensation and hence, are implicated
in the associated autonomic changes characterized by increased
sympathetic outflow. For a detailed review of the central
pathways implicated in nausea, see Stern et al. (2011) and Koch
and Hasler (2017).
Healthy volunteers and patients reporting nausea also
have a number of physiological changes often referred to as
“prodromata of vomiting.” The main ones are cold sweating
(forehead) and pale skin pallor due to regional cutaneous
vasoconstriction, tachycardia and increased heart rate variability,
elevated plasma vasopressin (but not oxytocin) concentration
indicative of hypothalamic-posterior pituitary involvement, and
inhibition of gastric motility (see Stern et al., 2011, and Koch and
Hasler, 2017).
The relatively poor temporal resolution of studies which have
attempted to correlate physiological changes with the subject’s
reporting of nausea means that for elevated plasma vasopressin,
gastric dysrhythmia and delayed gastric emptying, there is debate
about the extent to which each contributes to the genesis of
the sensation of nausea or are simply a component of the
physiological response to activation of the emetic pathways
(Stern et al., 2011; Andrews and Sanger, 2014). Resolving this
“cause-consequence” conundrum is important for identifying
which patient groups require therapeutic approaches that are
directed centrally or peripherally.
Nausea is recognized as poorly treated in comparison to
vomiting (Andrews and Sanger, 2014) and has been described
as a “neglected symptom” during treatment of cancer patients
(e.g., Foubert and Vaessen, 2005; Greaves et al., 2009; Jones
et al., 2011). It is also one of the defining symptoms in the
common, poorly-treated conditions of gastroparesis, functional
dyspepsia and chronic unexplained nausea and vomiting (Sanger
and Pasricha, 2017). However, such prevalence does not seem to
have stimulated research to improve our understanding of the
pathways involved in the etiology of nausea.
EARLY SERENDIPIDOUS DISCOVERIES OF
ANTI-EMETIC DRUGS
The original drive to identify anti-emetic drugs most likely
originated with the desire to block sea-sickness, with references
to treatments in Classical Greek and Roman literature (Huppert
et al., 2016) and more recently, Shakespeare (Cymbeline III, iv,
186; Kail, 1986). These and later attempts to block nausea and
vomiting prior to and during World War II (WWII, 1939–1945)
were largely based on traditional, historic and unproven remedies
for sea-sickness, with more than 40 treatments identified based
on publications in the Lancet between 1828 and 1928 (Reason
and Brand, 1975). The only substances recognized in antiquity
and pre-WWII and shown subsequently to have efficacy, are
atropine and hyoscine (see below). This required development
of methodologies for objective assessment of sea-sickness at sea
and methods for induction of motion sickness in controlled
laboratory conditions in humans and animals (McEachern et al.,
1942; Noble, 1945; Babkin et al., 1946; Holling, 1947; Brand
and Perry, 1966). The drug trials methodology developed by
the United Kingdom military and the Medical Research Council
became a model for drug trials in other areas.
By 1976, a series of largely serendipitous developments
identified four categories of anti-emetic drug (Gibbs 1976): (i)
Anticholinergic drugs (later shown to antagonize muscarinic
M3 and M5 receptors); (ii) Antihistamines (later shown to act
predominantly as antagonists at the histamine H1 receptor but
also at muscarinic receptors); (iii) Derivatives of phenothiazine
(shown to act as dopamine D2 receptor antagonists but also with
effects at other receptors); (iv) Metoclopramide, a drug derived
from the local anesthetic procainamide (initially described as a
D2 receptor antagonist before other activities were discovered
some year’s later; see below).
The early discoveries were made by testing in humans to
confirm anecdotal reports (e.g., the anti-cholinergic hyoscine) or
after rapid transition of a newly discovered molecule into the
clinic, when anti-emetic activity was unintentionally discovered
(e.g., antihistamines). Thereafter, animal studies began to appear
more frequently, beginning with their use in the discovery
of anti-emetic activity during routine screening for general
activity (the phenothiazines) and then to characterize the
actions of other dopamine2 (D2) receptor antagonists from
chemical programmes initially directed at controlling psychiatric
disorders.
The pharmacology (receptor affinities/potencies) and
structures of the major anti-emetic drugs discussed in the
sections below are summarized in Table 2.
Hyoscine and Scopolamine
The alkaloids hyoscyamine and hyoscine (also known as
scopolamine) are found in different plants from the family
Solanaceae (e.g., hyoscyamine in the deadly nightshade Atropa
belladonna and hyoscine from henbane, Hysoscyamus niger
(Henry, 1939). The toxic and medicinal properties of this plant
family have been known since antiquity (see Thearle and Pearn,
1982). Extraction of the naturally-occurring levorotatory isomer
of hyoscyamine leads to formation of the racemic mixture known
as atropine (Sneader, 2005).
Although this class of drug was suggested to be effective
against seasickness as long ago as 1881 (Irwin, 1881) it was
not until WWII that structured trials investigated the activity of
potential anti-emetic medications including hyoscine, atropine,
the different enantiomers of hyoscyamine, phenobarbitone,
sodium hydantoinate, chloretone, syntropan, hexobarbitone, and
methidrine (Reason and Brand, 1975). The trials occurred using
mine sweepers sent to sea in rough weather and positive
responders were those who did not experience nausea and/or
vomiting. The results, for the first time, demonstrated the
preventative efficacy of hyoscine in particular and also atropine
and the l-isomer of hyoscyamine (Holling et al., 1944; Holling,
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1947). These studies were rapidly followed by demonstration
of the anti-emetic efficacy of hyoscine among soldiers in
assault craft during tropical conditions (Hill and Guest, 1945).
Today, drugs such as scopolamine are widely available for the
treatment of all causes of motion sickness, manufactured by
different companies in oral formulations and in more convenient
formulations for anyone already experiencing nausea, such as
transdermal patches and nasal sprays (Spinks and Wasiak,
2011; Golding and Gresty, 2015). Following identification of
the different human muscarinic receptor subtypes (Huang
et al., 2001) these drugs have been shown to act most
notably at the M3 and M5 receptors which mediate cholinergic
activity within the vestibular input to the vestibular nuclei and
probably also within brainstem pathways integrating vomiting
such as the NTS (Golding and Stott, 1997; Soto and Vega,
2010)
Antihistamines
The discovery of the “antihistamines” (the term histamine
receptor antagonist was not introduced until 1966; Ash and
Schild, 1966) was initiated by academic curiosity in 1937 (at
the time compounds were known to block the actions of
adrenaline and acetylcholine, so why not histamine?) and then
rapidly further developed by the pharmaceutical industry. Initial
success was achieved by Rhône-Poulenc Laboratories (Tables 1,
2) screening “libraries” of compounds previously synthesized
during a search for therapeutic alternatives to the anti-malaria
drug quinine (from compounds traditionally used in the dying
industry but known to exert anti-septic, anti-helminthic and
anti-malarial activity), the supply of which was hindered by
blockades imposed on Germany during WWI and then in
WWII by Japanese expansion into South-East Asia (López-
Muñoz et al., 2005). The first antihistamine to treat anaphylaxis
and allergic reactions was phenbenzamine (also known as
antergan), introduced into the clinic by Rhône-Poulenc in
1942. This was followed by diphenhydramine, chlorpheniramine,
brompheniramine, promethazine and cyclizine (Emanuel, 1999;
Sneader, 2005; Church and Church, 2013). Notably, H1 receptor
antagonism also supresses a number of different pathways
within the brain, including those involved in arousal, leading
to drowsiness, somnolence and sedation. As a counter-measure,
dimenhydrinate (Dramamine) was introduced by G.D. Searle &
Co, consisting of diphenhydramine with 8-chlorotheophylline
(a mild stimulant and derivative of theophylline). Later,
in the 1980s, other compounds were identified with poor
ability to cross the blood brain barrier, the so-called “second
generation” H1 receptor antagonists, which do not have
anti-emetic activity (Slater et al., 1999; Simons and Simons,
2011).
The discovery of antiemetic activity among the first generation
antihistamine drugs was serendipitous. Dimenhydrinate
(Dramamine) was undergoing evaluation in 1947 as a potential
treatment of hay fever and urticaria. Among the patients
receiving the drug was a pregnant woman who suffered from
car sickness all her life. However, if she took dimenhydrinate a
few minutes before boarding a tramcar she remained symptom-
free; placebo was ineffective (Gay and Carliner, 1949). Next
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year (1948) G.D. Searle & Co conducted a trial in which
dimenhydrinate or placebo was given for 10 days or as a
successful rescue therapy to 485 male USA troops crossing
the Atlantic during “a rough passage” in the General Ballou,
a converted freight ship (Gay and Carliner, 1949). In 1949
diphenhydramine itself (Benadryl) was shown to alleviate nausea
and vomiting induced by streptomycin in four patients with
pulmonary tuberculosis (Bignall and Crofton, 1949). These trials
established the use of antihistaminic drugs as treatments of
motion sickness and indicated that they may also be effective
against emesis induced by other challenges. Cyclizine, developed
in 1947 by Burroughs Wellcome, was shown to prevent sea- and
air-sickness in 1952–1953 (see Norton et al., 1954 for references
and data on the autonomic pharmacology of cyclizine) and has
the notable history of being taken to the moon as a treatment for
space sickness (Figure 6).
The first generation “antihistamines” (used to treat various
allergic conditions; Simons and Simons, 2011) were effective
against motion sickness, nausea and vomiting caused by
labyrinthine disturbances (e.g., labyrinthitis and fenestration
operations; Wang, 1965) and were investigated as anti-emetics
in a number of other clinical settings (e.g., PONV, see Palazzo
and Strunin, 1984; pregnancy, see Fairweather, 1978 and also
Bhargava and Dixit, 1968, for pre-clinical studies). As anti-
emetic drugs they are effective because they block H1 receptors
in the vestibular system and also in the brainstem integrative
circuitry (“vomiting center”) (Takatani et al., 1983; Soto and
Vega, 2010). However, for some compounds, additional anti-
emetic activity is thought to be due to their additional ability to
antagonize at muscarinic receptors, perhaps not surprising, given
the origin of the early compounds from a chemical template used
to identify “adrenergic” and “cholinergic” antagonists (Liu et al.,
2006). For example, in addition to antagonizing at the human
H1 receptor (Ki 12.6 nM), diphenhydramine also inhibits M2
receptors (estimated Ki 80 nM) and displaces QNB binding in
the cerebral cortex (Ki 280 nM; Kubo et al., 1987; Booth et al.,
2002; Liu et al., 2006). Similarly, cyclizine and promethazine
antagonize at the human H1 receptor (respectively, Ki-values of
4.44 and 0.24 nM; Chazot et al., 2017) and appear to have an
ability to inhibit the functions of acetylcholine (Norton et al.,
1954). These drugs had no ability to prevent the vomiting
initiated by apomorphine, a D2 receptor agonist acting on the
AP (see Carpenter et al., 1983 and also Borison and Wang 1953
and Borison, 1989 for review of evidence on the effect of area
postrema ablation on the emetic response to apomorphine).
Histamine1 receptor antagonists, in addition to illustrating
how the pharmacological profile of compounds may change
from that originally described, are also examples of a more
fundamental shift in pharmacological characterization. Although
the agents described above such as diphenhydramine are
commonly referred to as H1 receptor “antagonists,” modern
pharmacology now classifies them as “inverse agonists” (Bakker
et al., 2007; Simons and Simons, 2011) but the implications of
this for understanding both the mechanisms of emesis and the
anti-emetic effects of different H1 “antagonists” have not yet been
considered (Tu et al., 2017).
Phenothiazines
The term “phenothiazines” refers to compounds with a
nucleus of two benzene rings linked by a sulfur and a
FIGURE 6 | Photograph of the packaging for Marzine (cyclizine, developed in 1947) indicating its use by NASA during the Apollo moon missions. With permission:
Wellcome collection, Wellcome Library (WF/M/PL/191), London, United Kingdom.
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nitrogen atom to form a heterocyclic 3-ring compound, with
phenothiazine itself first synthesized in 1883 (see Wang, 1965
for review). Chlorpromazine (Thorazine) was discovered from
the observation that certain anti-histamines, in addition to
prolonging sleep induced by barbiturates, also reduced the
“shock” of surgery when given during anesthesia, somehow
depressing the nervous system to leave patients relatively
calm and relaxed during recovery. Re-examination of the
antihistamines to optimize the “anti-shock” property (e.g., by
testing for an increase in time required for trained rats to climb
a vertical rope for food) led to synthesis of chlorpromazine
(or 4560-R.P) in 1946 (Sneader, 2005). This compound had
low antihistamine activity but blocked the effect of adrenaline
on blood pressure and in research within SmithKline and
French, inhibited conditioned reflexes in rats. The compound
also prevented emesis evoked by apomorphine, acting on the
AP in dogs (Glaviano and Wang, 1955). Apomorphine is
primarily considered to be a D2 receptor agonist but it is now
more accurately defined as a potent agonist at the D2 receptor
subfamily (D2, D3, D4) and D5 receptors, with additional affinity
for alpha1- and alpha2-adrenoceptors, 5-HT1A and 5-HT2 (5-
HT2A, 5-HT2B, 5-HT2C) receptors (Millan et al., 2002).
The pharmacological data on chlorpromazine, generated by
Rhône-Poulenc in 1951, were published (Courvoisier et al., 1953)
after the first clinical evaluation for treatment of “surgical shock”
in 1952. The commercial name for chlorpromazine (Largactil)
reflected its broad spectrum of activity (“large” = broad or
wide, “acti” = activity) (López-Muñoz et al., 2005). Later,
Carlsson (Nobel Prize Winner) and Lindqvist (1963) showed
that chlorpromazine binds to postsynaptic dopamine receptors,
launching the “dopamine hypothesis of schizophrenia” (in which
symptoms could be treated by blocking dopamine receptors in
post-synaptic neurons; Snyder et al., 1974) and revolutionizing
treatment of psychiatric disorders.
Chlorpromazine was originally used to treat “neurosis”
(sedation in psychiatric patients) and as pre-anesthetic
medication, inhibiting nausea and vomiting, “shock” and
augmenting the effects of anesthetics (Moyer et al., 1955).
The anti-emetic activity of chlorpromazine was evaluated
in more detail by Boyd et al. (1953, 1954) using dogs and
apomorphine. This work was initiated after Prof. R. Paul
(Faculté libre des Sciences d’Angers) visited his laboratory
in November 1951, during which he described experiments
at Rhone-Poulenc, as yet unpublished, showing 4560-R.P
potentiating the action of sedatives and inhibiting apomorphine-
induced vomiting in dogs. Prof. Paul arranged to have some
sent to his laboratory, so its anti-emetic activity could be
compared with promethazine, a structurally-related compound
the authors had previously reported to have limited anti-
emetic activity. The results clearly demonstrated the ability of
chlorpromazine to prevent apomorphine-induced emesis in
dogs. Contemporaneously, Brand et al. (1954) reported similar
findings in dogs, using apomorphine, morphine and ergot as the
emetic stimuli, but failed to prevent emesis evoked by copper
sulfate or inhibit the response to any emetic stimulus in cats. In
addition, the structurally related antihistamine, promethazine
(Phenergan) had no ability to inhibit apomorphine-induced
emesis. These data were consistent with Schmidt et al.
(1953) who used dimenhydrinate and diphenhydramine.
Later, a more detailed comparison using a number of
phenothiazines (chloropromazine, promazine, trifluoperazine,
levomepromazine, prochlorpromazine), trimethoxybenzamide,
antihistamines (perphenazine, thiethylperazine, dimenhydrate,
cyclizine), and hyoscine (Wyant, 1962) confirmed and extended
these observations in dogs, demonstrating the ability of
the phenothiazines and trimethoxybenzamide to prevent
apomorphine-induce vomiting but to have lower activity against
emesis evoked by intra-gastric copper sulfate, whereas the reverse
was demonstrated by the antihistamines and by atropine.
These data were interpreted by reference to a series
of experiments into the mechanisms and pharmacology of
vomiting, reviewed by Borison and Wang (1953). The authors
determined that vomiting induced by apomorphine (primarily a
D2 receptor agonist; see earlier) was caused by direct stimulation
of the AP, considered the site at which emetic substances in the
blood could induce emesis. Thus, chlorpromazine and the other
phenothiazine derivatives acted primarily by blocking dopamine
receptors (the term D2 receptor was introduced by Kebabian and
Calne, 1979) and although previously suggested, it was not until
1981 that the presence of D2 receptors within the AP of dogs was
confirmed (Stefanini and Clement-Cormier, 1981). The drugs
also exerted some general sedative effects, but failed to prevent
emesis induced by intra-gastric copper sulfate via visceral afferent
activation.
Chlorpromazine was first evaluated as an anti-emetic in
humans by cautious administration to patients with terminal
cancer or uremia and then, following success, it was given
to patients with a range of disorders, including labyrinthitis,
psychological vomiting and pregnancy sickness, in addition to
patients suffering from vomiting induced by a variety of drugs
(Friend and Cummins, 1953, 1954).
Wampler (1983) provides the structures of the different
phenothiazines and discusses their relative efficacies and adverse
events. In summary, there is little evidence for differences in
anti-emetic activity but differences in “anti-adrenergic,” “anti-
histaminic,” and “anti-serotonin” activities confer variations in
side-effects of sedation and hypotension. The strong “anti-
adrenergic” activity of chlorpromazine, for example, was
associated with hypotensive side-effects. Today, chlorpromazine
has been shown to have approximately similar affinity for
human H1, α-adrenoceptor2B, D2, D3 and 5-HT2C receptors
(acting as an antagonist) and for 5-HT2A and D5 receptors,
acting as an inverse agonist4 Examples of piperazine side-
chain phenothiazines that have potent antiemetic activity include
perphenazine, prochlorperazine and thiethylperazine maleate.
These drugs (particularly prochlorperazine) were rapidly adopted
for clinical use in a number of settings including anti-cancer
chemotherapy, later becoming the comparator for newer agents
(e.g., metoclopramide, cannabinoids; see Harris and Cantwell,
1986).
4http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=
biology&ligandId=83
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Metoclopramide
This drug was identified by Laboratoires Delagrange in France
in the mid-1950s, during a programme aimed at improving
the properties of procainamide, a cardiac anti-arrhythmic and
local anesthetic drug derived from procaine. Although some
anti-emetic activity was known to exist within this class of
molecule, chlorination of the benzene ring of procainamide (2-
chloroprocainamide) significantly increased anti-emetic activity
in dogs. However, more interesting was the absence of the
sedative activity of the phenothiazine structures prompting
an evaluation of related structures. In particular, methoxy-
2-chloro-5-procainamide or metoclopramide, had negligible
local anesthetic or cardiac anti-arrhythmic activity but an
ability to inhibit emesis in dogs evoked by apomorphine and
hydergine, in addition to copper sulfate (Justin-Besancon et al.,
1964). Soon after, metoclopramide was found to stimulate
gastric emptying, speed the rate of transit through the
small intestine and reduce symptoms associated with various
upper digestive tract disorders (Boisson and Albot, 1966;
Robinson, 1973; Schulze-Delrieu, 1979; Gralla, 1983; Sanger
and King, 1988). Between 1967 and 1971 several clinical trials
evaluated the ability of metoclopramide to inhibit emesis,
mostly in patients experiencing PONV, with perphenazine,
trimethobenzamide, prochlorperazine and perphenazine as the
comparators (Robinson, 1973). Delagrange undertook limited
marketing of metoclopramide, also licensing to A. H. Robins
(later acquired by American Home Products, which changed
its name to Wyeth) for the USA markets, and with some
initial skepticism over its wide range of potential clinical usage
(Robinson, 1973), to Beecham Pharmaceuticals in the UK.
As dopamine receptors were characterized (Kebabian and
Calne, 1979), metoclopramide was shown to be a D2 receptor
antagonist, selective over the D3 receptor and the α1-
adrenoceptor (Rosenfeld et al., 1982; Andrews and Sanger,
2014). The drug found widespread use as an anti-emetic
(e.g., during post-operative care or for patients with gastritis,
migraine, dysmenorrhea and drug- or treatment-induced forms
of emesis including that caused by anesthesia, radiation and
some anti-cancer chemotherapies) and as a stimulant of upper
gut motility (e.g., patients with gastro-esophageal reflux disease,
gastroparesis, and functional dyspepsia; Pinder et al., 1976;
Harrington et al., 1983). Initially, both the anti-emetic and
prokinetic activities were attributed to dopamine receptor
antagonism (Table 3). Although a major drug (there are now
many generic versions across the world), its limited central
action as an anti-emetic is, nevertheless, illustrated by its relative
ineffectiveness in motion sickness. Further, at conventional doses
(20mg × 3 orally), the drug showed little or no anti-emetic
superiority over placebo or prochlorperazine, when evaluated
against the highly emetogenic agent cisplatin (e.g., Moertel
and Reitemeier 1969), a relatively new anti-cancer drug at the
time.
During the 1980s it was discovered that metoclopramide
possessed an additional ability to stimulate gastric motility by
activating 5-HT4 receptors and at higher concentrations than
those required to antagonize at the D2 receptor, acting as a
5-HT3 receptor antagonist (Sanger, 2009; see below). The former
provided the mechanism by which metoclopramide stimulated
GI motility and the latter heralded the development of new anti-
emetic treatments and a revolution in care of cancer patients.
These developments occurred during a time when 5-HT receptor
pharmacology was being redefined.
The classification of 5-HT receptors began in 1957 when
using guinea-pig ileum as their model, Gaddum and Picarelli
defined a 5-HT M receptor (neuronally-mediated muscle
contractions, blocked by morphine and also by atropine,
cocaine, and methadone, even after dibenzyline) and a 5-
HT D receptor (non-neuronally-mediated smooth muscle
contractions, blocked by dibenzyline and also by lysergic
acid diethylamide, dihydroergotamine, and 5-benzyloxygramine,
even after morphine; Gaddum and Picarelli, 1957). In 1986
the classification was updated and three receptors defined: 5-
HT2 (5-HT D), 5-HT3 (5-HT M) and a tentative “5-HT1−like”
receptor, with similarities to a heterogeneous group of 5-HT1
(high affinity) binding sites (Bradley et al., 1986). Today, seven
different 5-HT receptors have been cloned and characterized,
with subtypes for some of these. All are GPCRs except 5-HT3,
a ligand-gated cation channel with potentially heterogeneous
subunits (5-HT3A-E; Holbrook et al., 2009).
In the 1980s a growing understanding of the mechanisms
of action of metoclopramide became a significant factor in
the discovery of the 5-HT4 receptor. Firstly, it became clear
that D2 receptor antagonism could not fully explain how
metoclopramide increased GI motility; for example, the more
selective D2 receptor antagonist domperidone did not mimic
the ability of metoclopramide to facilitate cholinergic activity
in human isolated stomach, thought to model the cholinergic-
mediated gastric prokinetic activity of this drug (Sanger, 1985a).
Thus, it was argued that metoclopramide acted on cholinergic
nerves within the enteric nervous system (ENS), but not
necessarily on other cholinergic neurons outside the ENS.
Clearly, this activity in human isolated stomach was independent
of brain function, consistent with the inability of vagotomy
to prevent the prokinetic effects of metoclopramide (Jacoby
and Brodie 1967). These and other experiments demonstrated
that metoclopramide facilitated ongoing cholinergic activity,
increasing the release of acetylcholine (ACh) rather than
directly stimulating muscarinic receptors (Sanger, 2017). This
activity was not due to antagonism at pre-junctional muscarinic
receptors, was not blocked by antagonists at the adrenoceptors
or D2 receptors, or by antagonists at various other receptors
and mechanisms. Instead, relatively high concentrations of 5-
HT mimicked the response and non-selective ligands for 5-HT
receptors mimicked or blocked this action of metoclopramide
(Sanger, 1985b,c, 1987a); the notable exception was the failure
to mimic or inhibit with a 5-HT3 receptor antagonist, leading
to the proposal that metoclopramide and related compounds
such as renzapride, facilitated cholinergic activity within the
ENS by activating a “myenteric 5-HT-like receptor” (Sanger,
1987a,b). This was quickly linked to a “non-classical” 5-HT
receptor identified by Dumuis et al. (1998) in mouse embryo
colliculi neurons and in guinea pig hippocampal membranes
and later defined as the 5-HT4 receptor (Bockaert et al.,
1992).
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TABLE 3 | Changing understanding of the role of gastric motility in the genesis of nausea and vomiting: Influences on drug discovery.
CONCEPT: Gastric prokinetics help patients with delayed gastric
emptying including functional dyspepsia/gastroparesis (multiple
symptoms, including nausea, vomiting, early satiety)
Mid-1950s
Metoclopramide
synthesized1
5-HT4 receptor agonists
Metoclopramide
• 5-HT4 agonist, D2 antagonist (later shown to be a 5-HT3 antagonist)
2
• Used in GERD, functional dyspepsia, gastroparesis; the only prescribed drug
for gastroparesis in the USA3
CURRENT STATUS:
1. Gastric Prokinetics (5-HT4 and motilin agonists)
useful in patients requiring more rapid delivery of
(for example) orally administered drugs to the
intestine17
2. No consistent correlation between symptoms (e.g.,
nausea, early satiety) and delayed gastric
emptying18
3. Gastric prokinetic and direct anti-emetic activity of
metoclopramide confuses mechanism of
therapeutic action
4. Role of erythromycin in the treatment of
gastroparesis uncertain
Other substituted
benzamides (eventually
shown to be 5-HT4
receptor agonists)
Cisapride
• 5-HT4 agonist, poor D2 antagonist (later shown to have similar affinity for
5-HT2A, 5-HT2B, α1-adrenoceptors and low affinity for 5-HT3 )
4,5
• 5-HT2A and 5-HT2B also implicated in mechanisms of emesis
6
• Reduced nausea in certain patients (now withdrawn)7,8
Explored Others
• Some animal data suggests ability to inhibit vomiting but non-selectivity of
action makes it difficult to interpret9
• Gastroprokinetic activity may oppose ability of 5-HT3 antagonists to inhibit
severe emesis in ferrets10
1989 Erythromycin
proposed to act as a
motilin receptor
agonist11
Motilin receptor agonists
Erythromycin
• Antibiotic drug used at lower doses to treat patients with gastroparesis and
delayed gastric emptying12
• Activates motilin receptors in enteric nervous system (prokinetic activity) and
vagus13,14,15
• Low doses may have anti-emetic activity; high doses cause emesis15
• Limited by potential to exacerbate bacterial resistance, prolong cardiac QTc
interval, and interact with cytochrome P450 CYP 3A412
• The selective motilin agonist camicinal shown to promote gastric emptying
and facilitate oral drug delivery in patients with Parkinson’s disease16
CONCEPT: Selective dopamine D2 antagonists are anti-emetic but also
increase gastric emptying, making them additionally useful treatments
of gastroparesis (as defined by delayed gastric emptying)
1974 Domperidone
synthesized19
Domperidone Increased gastric emptying in gastroparesis20 Alleviates
symptoms of gastroparesis21 No effects on gastric emptying in healthy
volunteers22 or in patients requiring video capsule delivery to the small
intestine23 and no direct ability to influence contractility of human isolated
stomach24 Low risk of cardiac QTc prolongation25 Registered for use in many
countries but not in the USA21
CURRENT STATUS:
1. Domperidone still explored in treatment of
gastroparesis21
2. Selective 5-HT253 and NK1 antagonists
27 have anti-
emetic effects but do not increase gastric emptying
although they may have benefits in patients with
gastroparesis.
3. These data support a role for dopamine in
regulation of gastric motility in addition to emesis
during disease
CONCEPT: Ghrelin agonists increase gastric emptying, leading to
exploration of their potential to treat gastroparesis, enhanced by ability
to promote appetite/reduce emesis
1999 Ghrelin discovered
and sequenced28
• Increase gastric emptying in healthy volunteers and in patients with
gastroparesis but may not be sustained with long-term dosing29
• No direct ability to influence contractility of human isolated stomach30
• Increases appetite and reduced nausea in patients, including gastroparesis31
CURRENT STATUS:
1. Ghrelin agonists remain of interest because they
can reduce nausea and increase appetite29
CONCEPT: Dysrhythmic movements of the stomach cause nausea
and/or are the result of nausea
2017 Resurgence of
interest in the
relationships between
gastric dysrhythmia,
gastric emptying,
nausea and vomiting
and gastric pathology in
patient sub-groups
Gastric Dysrhythmia
• Association between nausea and dysrhythmia of gastric myoelectric activity
characterized using electrogastrography in several groups of patients,
strengthened by studies with dense recording arrays32,33
Interstitial Cells of Cajal (ICC)
• Responsible for electrical slow waves; damage associated with gastric
dysrhythmia (initiation, propagation)34
• Hypothesis: Nausea caused by vagal afferents detecting gastric dysrhythmia
and signaling to brain stem32,35
CURRENT STATUS:
1. Exploratory research of ICCs as drug targets
2. Improved clinical classification of patient groups
with delayed gastric emptying
1Justin-Besancon and Laville, 1964; 2Sanger, 2009; 3Camilleri et al., 2013; 4Briejer et al., 1995; 5Smith et al., 2008; 6Johnston et al., 2014; 7Creytens, 1984; 8Bergeron and Blier,
1994; 9Sanger et al., 2013; 10Miner et al., 1987; 11Peeters et al., 1989; 12Sanger et al., 2013; 13Broad et al., 2012; 14Broad and Sanger, 2013; 15Javid et al., 2013; 16Marrinan et al.,
2018; 17Sanger and Alpers, 2008; 18 Janssen et al., 2013; 19Champion et al., 1986; 20Ahmad et al., 2006; 21 Heckert and Parkman, 2018; 22Markey and Shafat, 2012; 23McFarlane
et al., 2018; 24Sanger, 1985c; 25Ortiz et al., 2015; 26Midani and Parkman, 2016; 27Pasricha et al., 2016; 28Kojima et al., 1999; 29Sanger and Furness, 2016; 30Broad et al., 2014;
31Camilleri and Acosta, 2015; 32Koch, 2014; 33O’Grady et al., 2012; 34Angeli et al., 2015; 35Sanger and Pasricha, 2017.
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FIGURE 7 | Two hypotheses for the relationship between disordered upper gastrointestinal tract motility and the sensation of nausea. These are not mutually
exclusive but the efficacy of drugs targeted at sites A and B will differ depending upon which mechanism is in operation. In hypothesis A (left hand panel) the
activation of central emetic pathways activates ascending pathways leading to the sensation of nausea, followed by descending autonomic pathways leading to
delayed gastric emptying. An anti-nausea drug targeted centrally (site A) would block both nausea and the peripheral motility changes, so there will be a secondary
return of gastric emptying to normal. In this hypothesis a drug targeted at site B may only have a small effect by reducing a positive reinforcing feedback from the
centrally-driven disruption of motility. In hypothesis B (right hand panel) disordered upper digestive tract motility, usually resulting from disease (e.g., diabetic
gastroparesis), is the primary driver for the genesis of nausea, leading to activation of visceral afferents or possibly the release of enteroendocrine agents into the blood
for subsequent activity at the area postrema. A drug acting on the upper digestive tract (site B) would normalize gastric motility and remove the primary drive for
nausea. Note that in this hypothesis, the “traditional prokinetic drugs” (with an exclusively peripheral action) have generally not been successful; potential alternatives
are indicated. In this hypothesis a drug acting at the central site A would also be likely to indirectly reduce nausea by preventing activation of central pathways. ENS,
enteric nervous system; ICC, interstitial cells of Cajal.
Domperidone
Among the antipsychotic compounds (including the
butyrophenone haloperidol, discovered in 1958 by Paul Janssen;
Sneader, 2005) Janssen Pharmaceutica (Tables 1, 2) developed in
the mid-1950s, some were effective antagonists at the dopamine
receptors in the AP involved in induction of vomiting. Since this
region of the brain has a relatively permeable blood-brain barrier,
a search was made for antagonists that did not cross this barrier
and hence, were less likely to evoke extrapyramidal side-effects
caused by antagonism of dopamine receptors within the brain.
Using the now-established model of apomorphine-induced
emesis in dogs, domperidone was identified in 1974 from the
butyrophenone class of molecules. The drug was erroneously
described as similar to metoclopramide (Champion et al., 1986;
perpetuating the belief that all of the actions of metoclopramide
must be due to antagonism of the effects of dopamine) and
marketed in 1982 (Champion et al., 1986; Barone, 1999) for
prevention of nausea and vomiting (Figure 7) including that
induced by anti-cancer chemotherapy, then as a gastroprokinetic
agent (Ahmad et al., 2006) and galactogogue. Later studies
showed that domperidone has a similar affinity for the human
D2 and D3 receptors (Ki-values, respectively, 12.6 and 4 nM
5),
no ability to interact with the 5-HT4 receptor but at slightly
higher concentrations acts as a α1-adrenoceptor antagonist (Ki
5http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=
biology&ligandId=965
of 71 nM: Keiser et al., 2009; see also Ennis and Cox 1980; Ison
and Peroutka, 1986).
Investigation of the utility of dopamine receptor antagonists
as anti-emetics continues with investigations of other D2/D3
receptor antagonists, such as amisulpride (Kranke et al., 2013)
and ATC-19066, aiming primarily to achieve an improved safety
profile over domperidone (i.e., its cytochrome P450 interaction
liability and occasional reports of prolongation of cardiac QTc
intervals; Ortiz et al., 2015) and gain access to patients in the USA
(where domperidone is not registered) as well as the rest of the
world, for treatment of gastroparesis.
Dexamethasone; A Synthetic
Glucocorticoid
Baker et al. (1979) found that dexamethasone (10mg) reduced
vomiting caused by different cytotoxic anti-cancer drugs
but it was suggested that the associated euphoria played
a role. A pilot study using methylprednisolone to inhibit
prostaglandin release (Rich et al., 1980) also showed efficacy
(in combination with chlorpromazine or prochlorperazine) in
patients receiving cisplatin-based therapy. Later studies using
high-dose dexamethasone in patients receiving cisplatin alone or
in combination with other cytotoxic drugs reported impressive
responses with excellent or good control of nausea and vomiting
in 50% of patients who had failed on standard anti-emetics and
6https://www.pharmpro.com/news/2016/07/takeda-altos-therapeutics-partner-
develop-gastroparesis-treatment
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71% in patients who had not received anti-emetics previously
(Aapro and Alberts, 1981). Notably, synthetic corticosteroids do
not inhibit the acute, rapid-onset forms of vomiting induced by
apomorphine or ipecacuanha (Axelsson et al., 2003; Sam et al.,
2003), suggesting involvement of an “inflammatory” component
in the mechanisms of chemotherapy-induced emesis (Sanger and
Andrews, 2006).
Although now widely used in combination with other anti-
emetic drugs the mechanism and site of action is still not clear.
One suggestion is that dexamethasone may supress eicosanoid
metabolism, inflammation and edema induced by chemo-
radiotherapy (Andrews and Rudd, 2016; see Chu et al., 2014 for
review).
Cannabinoids
In the early 1970s, anecdotal reports emerged of reduced nausea
and vomiting by marijuana-users undergoing chemotherapy
for Hodgkin’s disease, leading to clinical evaluation of the anti-
emetic use of marijuana and THC (1-9-tetrahydrocannabinol,
the major psychoactive constituent) in cancer patients
receiving chemotherapy (Sallen et al., 1975; Vincent et al.,
1983; Parker et al., 2011). Thereafter, the Food and Drug
Administration (FDA) was recommended by the Oncologic
Drug Advisory Committee to classify THC for use against
refractory chemotherapy-induced emesis (Vincent et al., 1983).
Cannabinoids (THC, nabilone, levonantrodol) were extensively
investigated as anti-emetics in anti-cancer chemotherapy in
the late 1970s and early 1980s with a 1981 survey indicating
THC inclusion in 26.5% of studies, intermediate between
prochlorperazine (41.2%) and metoclopramide (20.6%; Penta
et al., 1981). Although cannabinoids were superior to placebo
and prochlorperazine, they were not pursued at the time because
of side-effects and probably also because of the discovery of the
anti-emetic efficacy of 5-HT3 receptor antagonists a few years
later (see below).
Developments in cannabinoid receptor pharmacology and
the availability of selective ligands prompted a resurgence of
interest in the anti-emetic effects of cannabinoids (Darmani,
2001; Simoneau et al., 2001) and particularly their potential in
treatment of chemotherapy-induced nausea (Rock and Parker,
2016). These agents have been shown to be effective against
vomiting and behaviors suggestive of nausea (see below) in
several animal models (ferret, least shrew, house musk shrew,
rat). In contrast to other agents discussed above, they act
as a receptor agonist, activating CB1 receptors in the dorsal
vagal complex of the brainstem (Van Sickle et al., 2003) and
the visceral insular cortex (Limebeer et al., 2012). The clinical
potential of the selective CB1 receptor agonists remains to be
evaluated.
THE 1980s: A NEW ERA IN CONTROL OF
NAUSEA AND VOMITING PROMPTED BY
CHANGES IN CHEMOTHERAPY
The rise in treatment of cancer from the 1960s to 1980 also
saw an increase in the number of anti-emetic studies in cancer
patients. From 1963 such studies increased from 1 to 12 per
annum in 1980 involving 25 different compounds alone or in
combination (Penta et al., 1981). An important driver was the
introduction of more effective, but unfortunately more emetic,
chemotherapy agents and in particular cisplatin, in 1971 (for
history of platinum salts, see Christie and Tansey, 2007). The
limited efficacy of anti-emetic drugs in these new therapeutic
regimes prompted research which led to the discovery of 5-
HT3 receptor antagonists, discussed below. A clinical study
published in 1984 (Plezia et al., 1984) reported that acute
vomiting induced by cisplatin-containing treatments could be
blocked by an “intensive five drug regime” (metoclopramide,
diphenhydramine, dexamethasone, diazepam, thiethylperazine);
by 1988 it was possible to achieve the same effect by intravenous
injection of a 5-HT3 receptor antagonist alone (Cassidy et al.,
1988). Although the introduction of cisplatin was a significant
stimulus for research into novel anti-emetic drugs it should not
be forgotten that radiation was also used to treat cancer and
also given prior to bone marrow transplantation, causing severe
nausea and vomiting (Danjoux et al., 1979); as late as 1978 general
anesthesia was being used to prevent acute vomiting resulting
from total body irradiation (Whitwam et al., 1978).
5-Hydroxytryptamine3 Receptor
Antagonists
Gylys et al. (1979) found that in conscious dogs, metoclopramide
more effectively inhibited vomiting evoked by cisplatin,
compared with chlorpromazine, haloperidol, domperidone,
or nabilone. Then in 1981, high intravenous doses of
metoclopramide were shown to reduce emesis in patients
receiving cisplatin for treatment of cancer, contrasting with
the poor effectiveness of prochlorperazine (Gralla et al., 1981).
The rationale for using the high dose was later explained by
Gralla (Christie and Tansey 2007). In brief, they realized that
the phenothiazines and the cannabinoids were not working well
so they needed another approach. In the USA, metoclopramide
was still a relatively new drug (it was widely used in Europe)
and since the dose was not well-established for the indication of
emesis it was decided to undertake a trial that escalated the dose
to maximize the chance of success. As Gralla recalled “I looked
at the world’s suicide literature and it looked as though it was
impossible to kill yourself with the drug, so that sounded good.”
Following the successful use of high-dose metoclopramide later
trials failed to replicate this activity with high doses of the D2
receptor antagonists domperidone (no change in protection but
serious side-effects noted; Tonato et al., 1985) and alizapride (less
effective than metoclopramide and caused severe hypotension;
Saller and Hellenbrecht, 1985). Thus, it began to seem unlikely
that high doses of metoclopramide achieved greater anti-emetic
activity simply because it somehow blocked D2 receptors in the
brain more effectively. At that time, one possibility was that the
ability of metoclopramide to increase gastric emptying may in
some way supplement the anti-emetic activity of this drug by
accelerating emptying of the stomach thus overcoming the gastric
stasis which accompanies nausea and precedes vomiting (see
Figure 7).
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The anti-emetic activity of metoclopramide was confirmed by
use of a ferret model of emesis to demonstrate efficacy against
different chemotherapeutic agents. The model was introduced
by Floczyk et al. (1982) using cisplatin as the emetic stimulus,
confirmed by Miner and Sanger (1986) and quickly extended
to study the effects of the chemotherapeutic drugs doxorubicin
and cyclophosphamide (Schurig et al., 1984; Miner et al., 1987)
and whole body irradiation (Gylys and Gidda 1986; Andrews
and Hawthorn 1987; Miner et al. 1987). The history of the use
of the ferret in anti-emetic research is reviewed Percie du Sert
and Andrews (2014) and this model has largely supplanted the
use of dogs as the first species in which novel anti-emetics are
studied and as a species for investigating emetic potential of
NCEs.
Research within Beecham Pharmaceuticals (Figure 2;Table 1)
using ferrets showed that cisplatin-induced emesis was unaffected
by domperidone but prevented by renzapride (BRL24924), a
molecule originally identified as a potent stimulant of gastric
motility (and an agonist at the “myenteric-like 5-HT receptor” or
5-HT4; see above) without ability to antagonize at the D2 receptor
(and subsequently shown to potently antagonize at the 5-HT M
or 5-HT3 receptor; Miner et al., 1986, 1987; Sanger, 1987a). Since
these experiments could not rule out the possibility that anti-
emetic activity was achieved by stimulation of gastric emptying
alone (Alphin et al., 1986) it was necessary to perform additional
experiments with the recently described selective 5-HT3 receptor
antagonist MDL72222 (a generous gift to G.J. Sanger from J.R.
Fozard, then at Merrel-Dow). The resultant complete control
of vomiting demonstrated for the first time, that powerful anti-
emetic activity could be achieved by 5-HT3 receptor antagonism
alone (Miner et al., 1986).
Prior to these studies in ferrets it had become clear
that metoclopramide could also interact with 5-HT receptors
which were, at the time, poorly understood. The drug
antagonized a neuronally-mediated action of 5-HT in guinea-
pig isolated colon and ileum (Bianchi et al., 1970; Birtley
and Baines, 1973; Bury and Mashford, 1976; Fozard and
Mobarok Ali, 1978), defining metoclopramide as a 5-HT M
receptor antagonist. Metoclopramide could also antagonize other
neuronally-mediated actions of 5-HT in the peripheral nervous
system, most notably, 5-HT-evoked tachycardia in rabbit isolated
heart or bradycardia in anesthetized rats (the von Bezold-
Jarisch reflex; Fozard and Mobarok Ali, 1978; Fozard, 1983).
Fozard and colleagues subsequently showed that (–)-cocaine and
structurally-related compounds also antagonized these actions
of 5-HT, leading to synthesis of MDL72222 from the chemical
template of cocaine by Merrell Dow (Figure 2; Tables 1, 2), the
first selective 5-HT3 receptor antagonist, then aimed at treatment
of migraine (Fozard, 1984).
The anti-emetic experiments, conducted in the laboratories
of Beecham Pharmaceuticals, were quickly replicated using
their own compound (the selective 5-HT3 receptor antagonist
BRL43694 or granisetron; Boyle et al., 1987; Bermudez et al.,
1988) and those from their competitors including: Glaxo
(GR38032F or ondansetron, a racemate designed for “a variety of
disorders including migraine” before being specifically patented
for treatment of depression, schizophrenia, anxiety and cognitive
disorders7); Sandoz (ICS 205-930 or tropisetron, designed for
treatment of migraine and later found to have some ability
to antagonize at the 5-HT4 receptor); and Merrell Dow
(MDL72222 or bemesetron, for treatment of migraine). These
studies led to the filing of a patent claiming the use of
these compounds for treatment of emesis Sanger and Miner
1988, successfully upheld over ondansetron (Cavella et al.,
1997, p. 27). Significantly, anti-emetic efficacy was not just
restricted to the control of cisplatin-induced-emesis but was
equally effective against different chemotherapeutic drugs (Miner
et al., 1987). Further, emesis could be controlled even after it
had begun (Miner et al., 1987), later of great importance in
positioning the 5-HT3 receptor antagonists as both prophylactic
treatments and for control of breakthrough emesis. An additional
control experiment, required at the time, was to demonstrate
that 5-HT3 receptor antagonism by granisetron did not also
prevent the anti-tumor activity of cisplatin (Goddard et al.,
1990). There was now no doubt that the experiments within
the Beecham Laboratories had demonstrated the role of the
5-HT3 receptor in the mechanisms by which chemo- and
radio-therapy evoke nausea and vomiting (reviewed in Sanger,
1990).
During this time and following the original abstract
highlighting the anti-emetic activity of renzapride (Miner et al.,
1986), experiments to demonstrate the anti-emetic activity of
the 5-HT3 receptor antagonist ICS 205-930 (Costall et al.,
1986) were swiftly sponsored by Sandoz, the manufacturer of
ICS 205-930 (see Christie and Tansey 2007). With respect to
ondansetron and tropisetron, these can therefore be regarded
as examples of “re-purposing” (bemesetron was not progressed
for treatment of emesis, the company preferring its follow-up
molecule MDL73147 or dolasetron; see Kirchner et al., 1993).
5-HT3 receptor antagonists prevent cytotoxic-associated
vomiting by blocking the ability of 5-HT, released from mucosal
enterochromaffin cells in the upper GI tract, to activate 5-
HT3 receptors on abdominal vagal nerve terminals and thereby
“desensitize” the vagus to the pro-emetic stimulatory actions of
5-HT and other substances (e.g., prostanoids) released during
the cytotoxic treatment (Andrews et al., 1988; see Andrews and
Rudd, 2016 for review of more recent evidence).
The more advanced stage of clinical and safety testing of
ondansetron (for CNS disorders) meant that this drug was first
to achieve registration by the FDA in 1991, followed in the
same year by granisetron in other countries and in particular,
by Japan in 1992. Later, there would be controversy over the
number of published clinical trials reported for ondansetron,
which appeared to have been reported more than once under
different authorship in different publications (Rennie, 1999),
calling for registration of clinical trials (now best practice).
Nevertheless, today, selective 5-HT3 receptor antagonists are
an essential component of anti-emetic therapy in patients
undergoing chemotherapy and together with the NK1 receptor
antagonists (see below) has revolutionized treatment of cancer
and reduced health care costs (Currow et al., 1997; Warr and
DeAngelis, 2009).
7https://www.google.co.ug/patents/US4973594
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Neurokinin1 (NK1) Receptor Antagonists
The widespread clinical use of 5-HT3 receptor antagonists to
treat chemotherapy-induced nausea and vomiting (CINV) and
to a lesser extent PONV, established the clinical need and hence,
the market value of an anti-emetic drug, which could exceed
one billion $US per annum, further stimulating interest in
this therapeutic area. Additionally, the primary efficacy of 5-
HT3 receptor antagonists in the acute phase of highly emetic
chemotherapy (e.g., cisplatin containing regimes) as compared
to the delayed phase where they appeared less efficacious, their
lower efficacy against nausea as compared to vomiting for both
CINV and PONV, and their lack of effect against emesis induced
by motion and apomorphine, illustrated the need for further
developments.
Substance P was identified by von Euler and Gaddum in
1931; the name originates from the phrase in their paper “This
standard preparation, which we call P. . . .” (von Euler and
Gaddum, 1931, p. 80). Over the last 40 years research into the
actions of substance P has been most closely associated with pain
pathways with focus on the neurokinin1(NK1) receptor as the
primary receptor for substance P in mammals (see Borsook et al.,
2012). Studies, largely in rodents, identified non-peptide small
molecules acting as antagonists at the NK1 receptor for potential
clinical use as analgesics. During this time, the involvement of
substance P (or other tachykinins) in mechanisms of nausea and
vomiting was largely overlooked, despite a body of literature
summarized in Table 4, which in many ways parallels that for its
involvement in pain (see Andrews and Rudd, 2004). Definitive
evidence for the involvement of substance P in emesis in animals
came only with the development of the non-peptide, brain
penetrant, NK1 receptor antagonists disclosed by Pfizer (CP-
96,435, Snider et al., 1991; CP-99,994, McLean et al., 1993). The
first published studies showing anti-emetic effects were in the
ferret by researchers at Glaxo (Bountra et al., 1993; Gardner et al.,
1994) and Merck (Tattersall et al., 1993, 1994) but using a Pfizer
compound (CP-99,994). These were followed by a detailed study
in the ferret, cat, house musk shrew and dog from Pfizer with
academic colleagues (Watson et al., 1995a,b). Overall the studies
demonstrated that NK1 receptor antagonists had a different
profile from 5-HT3 receptor antagonists (and muscarinic and
H1 receptor antagonists) in their ability to block both acute
and delayed cisplatin-induced emesis, to block emesis induced
by both peripherally (e.g., copper sulfate, abdominal vagal
afferent electrical stimulation) and centrally-acting stimuli (e.g.,
morphine, apomorphine) and also to reduce motion-induced
emesis. This unique preclinical profile rekindled interest in the
area of anti-emetics. However, a major question was whether
these encouraging pre-clinical findings (largely from the ferret)
would translate to the clinic. This question arose because despite
the pre-clinical data (largely from the rat) for the involvement
of Substance P in pain pathways, contemporaneous published
clinical studies of analgesic effects of NK1 receptor antagonists
were equivocal (e.g., Dionne et al., 1998; Reinhardt et al., 1998;
see Rupniak and Kramer, 1999; Hill, 2000; Borsook et al., 2012
for reviews). Among the suggested reasons for this failure (Laird
et al., 2000) was the potential for receptor/neurotransmitter
redundancy in pain-conducting systems (e.g., for the NK1,
NK2, NK3 receptors small differences in affinity for endogenous
ligands meant that “ligand promiscuity” was a real possibility;
Maggi, 2000; Sanger, 2004) or a mismatch between the measure
of “nociception” in animals and the human sensation of pain.
A key issue in increasing the likelihood that data obtained in
the ferret would translate was the early recognition of marked
species differences in NK1 receptor pharmacology with some
compounds having a relatively high affinity at the rat receptor
compared the human NK1 receptor (e.g., RP67580) whereas
others had a relatively high affinity at the human compared to
the rat receptor (e.g., L743310; see Table 1, p. 382, Andrews
and Rudd 2004). Taking CP-99,994 as an example, as it was the
compound most widely used in establishing the in vivo effects
of NK1 receptor antagonists, it has relatively high affinity at
the human (Ki 0.3 nM) and ferret (Ki 1.7 nM) NK1 receptors
in contrast to the rat receptor (Ki 111 nM); a similar pattern
is found with other NK1 receptor antagonists (Andrews and
Rudd 2004). In vitro autoradiographic studies showed that CP-
99,994 displaced [3H]-substance P from the ferret brainstem
including the AP and the subnucleus gelatinosus region of
the NTS in a concentration-related manner over 0.1–100 nM
(Watson et al., 1995a). It should be noted that technological
advances in brain imaging now make it possible to study ligand-
receptor interactions in vivo in animals (e.g., Chin et al., 2006)
and humans (e.g., Borsook et al., 2012) facilitating compound and
clinical dose-selection and hopefully enhancing translation.
The first human study of an NK1 receptor antagonist was
published in 1997 (Kris et al., 1997), <4 years after the first
pre-clinical publication. This rapid time was facilitated by prior
safety studies required for the earlier analgesic studies (see above)
and illustrates why progress can sometimes be rapid if a drug
has already been investigated in another therapeutic area. In 17
patients undergoing highly emetogenic cisplatin chemotherapy
CP-122,721 was efficacious overall but the effect was particularly
marked (83% complete control) in the delayed phase of emesis.
Further studies in patients undergoing chemotherapy followed,
using other compounds (e.g., CJ-11,974, Hesketh et al., 1999; L-
54030 and L758298, Navari et al., 1999) and compounds were also
investigated for efficacy in PONV (CP-122, 721, Gesztesi et al.,
1998; GR-205171, Diemunsch et al., 1999).
Currently, four NK1 receptor antagonists are approved
for human clinical use: aprepitant, fosaprepritant
[intravenous formulation of aprepitant (see Hale et al.,
1998, for characterization)], rolapitant, and netupitant, the
primary differences being potency and duration of action. The
most recent MASCC/ESMO guidelines for high emetic-risk
chemotherapy (Herrstedt et al., 2017) recommend use of an
NK1 receptor antagonist in combination with a 5-HT3 receptor
antagonist and dexamethasone for optimal efficacy.
It is worthwhile noting that the NK1 receptor antagonist
maropitant (Benchaoui et al., 2007b) is marketed (Cerenia
TM
)
for prevention of acute vomiting in dogs. It has been used
for treatment of vomiting in dogs undergoing cisplatin-
chemotherapy (Vail et al., 2007) but also has efficacy against
vomiting in other indications including parvoviral enteritis and
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TABLE 4 | A summary of the key pieces of evidence implicating substance P and related tachykinins in emesis.
Date Evidence Species References Comment
1936 Substance P (SP) extracted from the
vagus
Dog von Euler, 1936 • The vagus had been implicated in the induction of emesis
by early animal studies (Hatcher, 1924) and studied in the
1920s (cited in Lewis, 1942) when induction of nausea was
reported in humans by stimulation of the vagus
• Subsequent demonstration in the vagus and nodose
ganglion of multiple species including human (e.g.,
Lundberg et al., 1978). Also vagal afferents terminating in
the nucleus tractus solitarius (NTS) shown to be source of
some of the Substance P in the dorsal brainstem (see
Andrews and Rudd, 2004)
1951 High levels of SP extracted from the
digestive tract mucosa
Dog Douglas et al.,
1951
• Digestive tract mucosa enterochromaffin cells shown to be
a rich source of 5-HT in a range of species in the 1950s,
accounting for the majority of 5-HT in the mammalian body
(Faustini, 1955; Erspamer and Testini, 1959)
1954 High concentrations of SP in the area
postrema (AP); Authors comment: “the AP
only contains active substances by virtue
of its chemoreceptive properties… One of
the functions of some parts of this tissue
may be to act as a chemoreceptor for
substances in the blood stream to convert
messages received in this way into
nervous impulses.”
Dog Amin et al., 1954 • Although the AP was implicated in emesis by older papers
(e.g., see Hatcher, 1924) the seminal paper by Wang and
Borison (1952) highlighted its role as a chemoreceptive
region of the brain
1963 Induction of emesis by subcutaneous
administration of eledoisin (a tachykinin
closely related to SP and extracted from
posterior salivary glands of the octopod
Eledone cirrhosa)
Dog Erspamer and
Glasser, 1963
• The frog skin tachykinin, pysalemin (subcutaneously and
intravenously) induced vomiting in the dog Bertaccini et al.
(1965) and intravenous SP was shown subsequently to
have a similar effect, although so did many other peptides
Carpenter et al. (1983, 1984)
1981 Immunohistochemical localization of SP in
the AP to varicose processes but absence
of SP-positive cell bodies
Rat Armstrong et al.,
1982
• Findings confirmed and extended by Pickel and Armstong
(1984) but as rodents lack an emetic reflex (but see text for
discussion) the relevance to emesis may have been
overlooked. Newton et al. (1985) confirmed and extended
the rat finding to the cat, a species with an emetic reflex so
potentially of more relevance to humans.
1981 High levels of SP in human brainstem
including area postrema
Human Cooper et al.,
1981
• A study in 1955 (i.e., a year after the (Amin et al., 1954) dog
study) had found little SP in the human AP and may have
led to the view that there were species differences,
resulting in dismissal of the potential clinical significance of
the dog study.
1983 Activation of AP neurons by ionophoretic
application of SP
Dog Carpenter et al.,
1983, 1984
• Electrophysiological evidence for excitatory effects of SP in
a relevant species, but numerous other peptides had
similar effects, possibly reducing the significance of the
observation
1984 Demonstration of high levels of SP
receptors in the nucleus tractus solitarius
and moderate levels in the area postrema
Rat Helke et al., 1984 • SP-sensitive receptors investigated using [125 I]Bolton-
Hunter SP
• NTS implicated in coordination of visceral and somatic
motor outputs for emesis and integration of afferent signals
prior to projection to more rostral brain regions (see text for
details)
1988 Induction of retching in the urethane
anesthetized ferret by topical application
of SP (0.1mM) to the fourth ventricle
Ferret Wood, 1988 • Proposed that the action was either directly on the AP or
via access to the dorsal NTS, particularly the subnucleus
gelatinosus. A subsequent study in conscious ferrets
showed that injection of SP into the NTS induced emesis
(Gardner et al., 1994)
(Continued)
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TABLE 4 | Continued
Date Evidence Species References Comment
1992 Acute administration of the ultrapotent
capsaicin analog (RTX) to the ferret has
anti-emetic effects against both centrally
and peripherally acting stimuli
Ferret Bhandari and
Andrews, 1992
• In the subsequent full paper (Andrews and Bhandhari,
1993) it was proposed that “the most likely mechanism to
account for the anti-emetic effects is that RTX induces a
depletion of a neurotransmitter, possibly substance P or
CGRP, at a central site in the emetic pathway”
1993 First preclinical publications showing
anti-emetic efficacy of a non-peptide NK1
receptor antagonists (CP-99,994)
Ferret Bountra et al.,
1993; Tattersall
et al., 1993
• These publications were from scientists at Glaxo and
Merck but the compound used (CP-99, 994) was a Pfizer
compound (Watson et al., 1995a,b). See text for details of
other compounds and discussion of spectrum of
anti-emetic effects.
1997 First clinical publication of anti-emetic
effects on a non-peptide NK1 receptor
antagonist (CP-122,721) against high
dose cisplatin chemotherapy
Human Kris et al., 1997 • This study supported the translation of ferret data to human
and demonstrated significant efficacy in the delayed phase,
in contrast to the effects of 5-HT3 receptor antagonists
(see text for details)
2003 Approval of Aprepitant (Emendr) by
European Medicines Evaluation Agency
and Food and Drug Administration for
treatment of emesis induced by cisplatin
chemotherapy
Human
For detailed discussion see Andrews and Rudd (2004).
pancreatitis (de la Puente-Redondo et al., 2007) as well as
blocking vomiting induced by hydromorphone when used as a
surgical premedication (Claude et al., 2014) and motion sickness
(Benchaoui et al., 2007a). Maropitant is available for prevention
of vomiting in cats (Batchelor et al., 2013). Other anti-emetics
used in humans such as metoclopramide and ondansetron have
also found veterinary use (Kenward et al., 2017).
A final note: Among all the proposed clinical indications for
NK1 receptor antagonists (especially pain, depression, anxiety,
emesis), based on animal and human data (Kramer et al.,
1998; Saria, 1999), only the anti-emetic indication successfully
translated to clinical usage. For emesis at least, this activity was
not subject to putative “promiscuity” among NK receptors for
endogenous ligands (see above); NK3 receptor antagonism did
not inhibit cisplatin-evoked emesis in ferrets (King and Sanger,
2005).
NK1 And 5-HT3 Receptor Crosstalk
Palonosetron (RS 25259-197) was synthesized and characterized
by Syntex Discovery Research (Clark et al., 1993; Eglen et al.,
1995), before being licensed to Eisai and Helsinn for co-
marketing in the USA in 2003 (the same year as aprepitant was
approved by the EMEA and FDA). The drug has a relatively
high binding affinity for the 5-HT3 receptor (Wong et al., 1995;
Muchatuta and Paech, 2009) and a long plasma half-life in
healthy volunteers (Stoltz et al., 2004; Muchatuta and Paech,
2009). Surprisingly, palonosetron was effective in both acute and
delayed phases of CINV. The drug did not antagonize the NK1
receptor (Wong et al., 1995) and since other 5-HT3 receptor
antagonists did not have the same efficacy profile, research
was initiated to explain these findings. This showed that in
contrast to the first generation of 5-HT3 receptor antagonists,
which are competitive receptor antagonists, palonosetron binds
allosterically to the receptor, exhibiting positive cooperativity;
the authors argued that the difference in structure between
palonosetron and the earlier 5-HT3 receptor antagonists may,
somehow, explain this difference (Rojas and Slusher, 2012).
Further experiments demonstrated a persistent ability to inhibit
receptor function after the drug was removed, triggering receptor
internalization of the drug-receptor complex into the cell (Rojas
et al., 2010). Since palonosetron remained bound to the 5-HT3
receptor, this internalization now persisted for much longer than
anticipated for a simple competitively-acting receptor ligand,
raising the possibility that the internalized complex could interact
and “crosstalk” with NK1 receptor signaling pathways, inhibiting
the functions of substance P (Rojas and Slusher, 2012; Rojas et al.,
2014). Furthermore, palonosetron inhibited the upregulation
of substance P expression in the nodose ganglia induced by
cisplatin in rats, whereas granisetron and other 5-HT3 receptor
antagonists did not (Rojas and Slusher, 2012).
Interestingly, a possible interaction between 5-HT3/NK1
receptors had been demonstrated 10 years previously by Minami
et al. (2001) using in vivo recording from ferret abdominal vagal
afferents (e.g., Minami et al., 2001). This study showed that
an NK1 receptor antagonist (CP-99,994) reduced the afferent
response to 5-HT and conversely the 5-HT3 receptor antagonist
granisetron reduced the afferent response to Substance P.
To date, palonosetron is the only 5-HT3 receptor antagonist
approved by the FDA for prevention of both acute and
delayed CINV. The combination of palonosetron with NK1
receptor antagonists such as netupitant therefore appears to have
synergistic activity and good efficacy against both “acute” and
“delayed” emesis (Rojas et al., 2014). Indeed, when these two
drugs are given together with dexamethasone, total control of
cisplatin-induced vomiting has been reported in the absence of
significant nausea (Aapro et al., 2014; Keating, 2015). Today,
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Helsinn markets an oral fixed-dose combination product of
netupitant with palonosetron (NEPA) for prevention of CINV.
The experience with palonosteron demonstrates that the
pharmacological profile of a compound defined at the time of
discovery does not necessarily predict the in vivo effects.
CHALLENGES IN IDENTIFICATION OF
NOVEL ANTI-EMETIC DRUGS
No Single Organ Target
Nausea and vomiting involve multiple organs and systems (e.g.,
visceral and somatic divisions of the peripheral nervous system,
the digestive tract and respiratory system), including the central
nervous system (CNS) which integrates the sensory inputs and
motor outputs. Thus, there is no obvious single physiological
pathway or organ to study, in contrast to asthma (airways),
peptic ulcer (gastric and duodenal mucosa) and angina (coronary
circulation). Pain, with sensory, behavioral, CNS, and motor
components would be the most analogous clinical problem to
nausea and vomiting.
The lack of a clear “target organ” means that it is difficult
to apply modern molecular techniques for target identification
and validation, and such methods have not (yet) contributed to
anti-emetic drug discovery. Nevertheless, twin and (Reavley et al.,
2006) genome-wide association studies (Hromatka et al., 2015)
of motion sickness begin to illustrate the potential for molecular
studies to provide insights into tractable targets.
Animal Models and Their Translational
Value
The commonly-used laboratory rodent species do not vomit
(Sanger et al., 2011; Horn et al., 2013) so most early research
used non-human primates (particularly the squirrel monkey in
motion sickness research) and dogs, with a few studies utilizing
cats. Although dogs have been used for emesis research for
at least 150 years (see Hatcher and Weiss, 1923 for review of
early literature), in the last 35 years ferrets and to a lesser
extent mink (both carnivores) have largely supplanted dogs for
emesis research (see Percie du Sert and Andrews, 2014 for review
of the history of their use in emesis research and references)
although cats continue to be used for studies of motion sickness
(e.g., Yates et al., 2014). The insectivore Suncus murinus (house
musk shrew) has also been utilized, largely because it is highly
sensitive to motion (Ueno et al., 1987, 1988) and its small size
(<100 g) reduces the amount of a novel compound that needs
to be synthesized for testing in vivo. Similarly, the least shrew
(Cryptotis parva) which only weighs ∼5 g has also been utilized
(e.g., Zhong et al., 2014). However, for most of these species
their genome has not been sequenced, hampering translation of
receptor pharmacology across species. It is also important to note
that for an animal model to have translational value for humans,
the species must respond to the same stimulus (preferably at
doses comparable to those used clinically), must cause emesis by
the same pathway/mechanism as in humans (bearing in mind
that pathways may exhibit plasticity as the result of disease and
the mechanism in humans may not be known) and must involve
the same neurotransmitter and receptor sub-type in the pathway.
A critical question related to translation is “Do Animals
Experience Nausea and if so, How could it be Measured?” The
mechanical act of vomiting is broadly similar in humans and
the laboratory animals. Until relatively recently, the ability of a
substance to block retching and vomiting in an animal was taken
as an indication that nausea was also likely to be blocked when
tested in humans. For example, as some behaviors accompanying
cytotoxic drug-induced emesis in ferrets were inhibited by
5-HT3 receptor antagonists (e.g., burrowing and backing-up
movements; Bermudez et al., 1988; Hawthorn and Cunningham,
1990; but see Lau et al., 2005a,b for more recent analysis) it
seemed reasonable to suggest that 5-HT3 receptor antagonists
could also have anti-nausea effects in humans. However, it has
since become apparent that 5-HT3 receptor antagonists have a
relatively lower efficacy against nausea induced by chemotherapy
as opposed to vomiting (Soukop, 1990). Research in animals
continues (there is considerable debate regarding nausea in
animals and the nature of the assumed sensory experience) and
many pre-clinical studies investigating mechanisms of emesis
now include one or more of the measurements argued to be
indices of nausea (e.g., Horn et al., 2011; Lu et al., 2017a,b; for
detailed discussion of the issues see Stern et al., 2011, Chapter
8; Andrews and Sanger, 2014). Additionally, in animals, post
mortem analysis of the pattern of activation of brain nuclei
indicated by c-Fos immunohistochemistry can also give insights
into which “higher” brain regions can be activated by an emetic,
giving some insight into possible sensory experiences which may
accompany vomiting and/or nausea (Lu et al., 2017b; Tu et al.,
2017).
The Challenges of Research on Nausea
and Vomiting in Humans
Studies of the physiology and pharmacology of nausea and
vomiting in healthy volunteers are not common and usually
involve use of relatively mild stimuli so only nausea is induced.
These include apomorphine (Isaacs and MacArthur, 1954),
ipecacuanha (Minton et al., 1993), and opioid receptor agonists
(Soergel et al., 2014) together with motion, most commonly in
the form of vection.
Although clinical trial design methodology is well-established,
improved methodology for real-time, more objective and
quantitative measurements of nausea and vomiting is needed in
humans to improve characterization of the side effects of new
treatments and better characterize the effects of anti-emetics, also
facilitating more valid comparisons with pre-clinical studies.
Four areas appear promising for human research: (i)
Improved understanding of the neuropharmacology of brain
pathways implicated in nausea using brain imaging techniques
combined with physiological studies of changes accompanying
nausea (e.g., heart rate variability, plasma vasopressin and gastric
motility); (ii) Analysis of large patient data sets to identify
relationships between symptoms (e.g., nausea, early satiety) and
underlying pathology (e.g., dysfunctional interstitial cells of Cajal
within the stomach wall; see below); (iii) Precise characterization
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of the efficacy of anti-emetics in specific patient sub-populations
so that molecular correlates can be identified (e.g., 5-HT3B
receptor gene (Tremblay et al., 2003) and ABCB1 polymorphisms
(Babaoglu et al., 2005; Tsuji et al., 2013) as predictors of 5-
HT3 receptor antagonist efficacy in CINV), potentially providing
data to develop personalized therapies; (iv) Identification of
the genomic/molecular basis for individual and population
differences in sensitivity to different emetic stimuli; for example
for motion sickness, which itself is a prognostic indicator for
other causes of emesis (e.g., Warr, 2014), there are inter-
individual (e.g., twin studies, Reavley et al., 2006), sex (female
sensitivity > male, Lentz and Collins, 1977) and ethnic (greater
sensitivity in Chinese subjects compared with African-American
and Caucasian subjects, Stern et al., 1983) differences. Genome-
wide association studies of large populations (>80,000 subjects)
have begun to identify single nucleotide polymorphisms (SNP)
associated with increased motion sickness sensitivity (Hromatka
et al., 2015) and SNPs in the opioid receptor gene (OPRM1) have
been associated with PONV (Sugino et al., 2014).
CURRENT AND FUTURE DIRECTIONS IN
RESEARCH: LESSONS FROM THE PAST
FOR THE FUTURE
Repurposing: Old Drugs for New
Treatments
A number of the drugs described above were not “designed”
as anti-emetics; this was discovered after their introduction
for different therapeutic uses. More recently, there is now a
growing list of other drugs which were originally used to treat
psychosis and depression, and which have subsequently been
shown to inhibit nausea and vomiting in several difficult-to-
treat indications, including patients receiving palliative care.
These include amitriptyline, levomepromazine, mirtazapine,
olanzapine, and gabapentin. Table 5 summarizes their discovery,
original use approved by the FDA, the key pharmacology and
their additional, “repurposed” use as anti-emetic drugs.
Nausea: Old and New Approaches (Table 3)
Nausea still remains relatively poorly treated in comparison to
vomiting in many clinical settings including CINV (e.g., Jordan
et al., 2016; Aapro, 2018) and there is an increasing recognition
in the literature of its importance as a symptom (Donovan et al.,
2016); a recent review on CINV posed the question “Time for
more emphasis on nausea?” (Ng et al., 2014).
Gastric Emptying as a Target
Delayed gastric emptying can occur in diverse disorders (e.g.,
chronic renal failure and Parkinson’s), but particularly those
with a digestive tract etiology (e.g., gastroparesis, functional
dyspepsia, scleroderma) in which nausea is also a symptom.
Although evidence for a causal relationship between the genesis
of nausea and delayed gastric emptying is inconsistent (Sanger
and Pasricha, 2017) there has been a widely held (but also
challenged, Sanger and Andrews, 2006; Sanger et al., 2013)
assumption since the 1960s that restoring gastric emptying will
alleviate the nausea (see McRitchie et al., 1984 for review);
this forms the rationale for preferential use of prokinetic (and
also anti-emetic) drugs such as metoclopramide (the longest
approved drug for treatment of gastroparesis; Schulze-Delrieu,
1979; Camilleri et al., 2013) and domperidone (Brogden et al.,
1982) to alleviate nausea (Figure 7). This approach has been
pursued more recently by exploiting the gastric prokinetic
properties of the antibiotic drugs erythromycin and azithromycin
(Broad and Sanger, 2013), providing another example of
“repurposing” and stimulating research into the prokinetic effects
of macrolides (Broad et al., 2012). Nevertheless, until the precise
mechanistic relationship between the various causes of delayed
gastric emptying (e.g., disruption of the ENS, e.g., diabetic enteric
neuropathy, Chandrasekharan and Srinivasan, 2007) and nausea
is understood in a range of disorders, approaches based on
prokinetics will continue to be more empirically, rather than
rationally based.
Gastric Dysrhythmia as a Target
Movements of the human stomach muscles are regulated or
“paced” by interstitial cells such as the interstitial cells of Cajal
(ICC) which exist as different syncytia within the stomach wall
(e.g., Rhee et al., 2011). In summary, these cells generate electrical
slow waves which are transmitted to smooth muscle via gap
junctions to create “waves” of muscle contraction that move
from the gastric corpus down to the pyloric regions, promoting
gastric emptying into the intestine (Blair et al., 2014). Increased
understanding of their role in the etiology of gastric dysrhythmias
linked to nausea (in which changes in functions lead to disrupted
patterns of movements within different ICC/muscle syncytia
without necessarily changing rates of gastric emptying; see
Sanger and Pasricha 2017), particularly in conditions such as
gastroparesis (Owyang and Hasler, 2002; Angeli et al., 2015),
makes them an increasingly attractive target. The ion channels
modulating functions of these cells (Lees-Green et al., 2011) are
of particular interest as drug targets.
Appetite and Nausea Relationship
Most recently, research has focussed on the concept that nausea
might be reduced by drugs which promote appetite, particularly
as nausea, vomiting, pain, early satiety and bloating are a
common symptom cluster in upper digestive tract disorders such
as chronic dyspepsia and gastroparesis (Revicki et al., 2009).
The hormone ghrelin has been shown to alleviate anorexia and
vomiting in animal models and reduce cachexia and nausea
in cancer patients, activities thought to be related to its ability
to promote appetite (and perhaps “hedonistic eating” via a
constitutively-active receptor; see Sanger and Furness, 2016).
In two Phase II studies in patients with diabetic gastroparesis
the ghrelin receptor agonist relamorelin, accelerated gastric
emptying and reduced vomiting frequency and severity (Lembo
et al., 2014, 2016).
Central Nervous System Pathways as a
Target
The sensation of nausea requires activation of pathways in
the cerebral hemispheres and most likely the cerebral cortex
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TABLE 5 | Summary of key drugs “repurposed” for the control of emesis.
Discovery Original use Summary of pharmacology Anti-emetic use
Amitriptyline
• Discovered by several
groups in 19601
• Tricyclic
antidepressant;
approved by the
FDA in 19612
• Inhibits 5-HT and noradrenaline transporters
• Also has affinity for the H1 receptor,
muscarinic receptors, the α1-adrenoceptor
and 5-HT2A receptor, at concentrations
similar to those which bind 5-HT and
noradrenaline transporter sites4
• Reduced symptoms in patients with chronic
nausea and vomiting (with pain as a predominant
symptom) and in diabetic patients with
unexplained vomiting4,5
Levomepromazine
• Originally described by
Rhone-Poulenc in 19566
• Phenothiazine
neuroleptic drug
• Can antagonize at H1, muscarinic M1/M2,
D1, D2, D3 and D4, receptors, the α1
adrenoceptor and the 5HT2 receptor
7,8
• Has found use in treatment of patients with
intractable nausea and vomiting receiving
palliative care where it is also used to treat severe
delirium or agitation at the end of life9
Mirtazapine (Org 3770)
• Synthesized in 200010 • Antidepressant
drug
• An antagonist at H1, alpha2 adrenoceptor,
5-HT2C, 5-HT2A and 5-HT3 receptors
11
• Has affinity for several GPCRs, but has
highest measurable affinity for
α2-adrenoceptors (IC50 order of potency: 2A
> 2C > 2B) and 5-HT2A and 5-HT2C
receptors (Ki order of potency 5-HT2C > 2A
> 7 > 1A (Table 2).
• Several case reports and small studies suggest
anti-emetic efficacy in patients undergoing
surgery, suffering from hyperemesis gravidarum,
chronic unexplained nausea and vomiting, and
severe gastroparesis unresponsive to
conventional treatments12,13,14
• Also used to treat vomiting and co-morbid anxiety
or depressive disorders in patients with chronic or
cyclical vomiting syndromes15
Olanzapine
• A thienobenzodiazepine
originally described by Eli
Lilly in 198016
• Atypical
antipsychotic
• Has affinity for M1, 5-HT2A, 5-HT2B,
5-HT2C, M4, H1 > M3, M2, D2 > D4, D1,
α1-adrenoceptor >5-HT
17,18,19
3
• Used to prevent and treat breakthrough
chemotherapy-induced emesis when given alone
and in combination with other anti-emetic
drugs20 including patients receiving palliative
care21,22
• For example, a significant improvement in nausea
reported when given together with 5-HT3 and
NK1 receptor antagonists
23,24
Gabapentin
• Synthesized in 1974 (by
Gerhard Satzinger) at
Parke-Davis (now owned
by
Warner-Lambert/Pfizer)
as potential epilepsy
drug, incorporating
γ-aminobutyric acid into a
lipophilic cyclohexane ring
to cross the blood-brain
barrier
• Approved by the
FDA in 1994 to
control partial
seizures and in
2002 for
conditions with
neuropathic
pain25,26
• No mechanistic studies in emesis but its
analgesic effects are attributed to blockade
of the α2/δ subunit of voltage-gated calcium
channels27
• First reported as a potential drug to treat nausea
in CINV in 2003 and subsequent studies have
extended this to PONV and possibly hyperemesis
gravidarum27,28
1Sneader, 2005; 2Fangmann et al., 2008; 3Owens et al., 1997; 4Prakash et al., 1998; 5Sawhney et al., 2007; 6Sigwald et al., 1956; 7Lal et al., 1993; 8Srivastava et al., 2009; 9Dietz
et al., 2013; 10Kennis et al., 2000; 11Anttila and Leinonen, 2001; 12Hasler, 2016; 13Kim et al., 2006; 14Kundu et al., 2014; 15Coskun and Alyanak, 2011; 16Chakrabarti et al., 1980;
17Bymaster et al., 1996; 18Navari, 2014; 19Leggio et al., 2016; 20Chiu et al., 2016; 21Atkinson, 2014; 22MacIntosh, 2016; 23Hocking and Kichenadasse, 2014; 24Navari, 2014; 25https://
www.chemistryworld.com/podcasts/gabapentin/1017577.article; 26Sirven, 2010; 27Guttuso et al., 2003; 28Guttuso, 2014.
(Farmer et al., 2015). To block nausea initiated by activation
of one of the classical input pathways (vestibular system, area
postrema, vagal afferents) will require a drug which acts at some
point along the pathway at which these outputs converge to
project information to the cerebral hemispheres. The closer the
drug acts to the cortical site of sensation genesis the greater
will be the probability of treating nausea irrespective of the
cause (including psychogenic). Although conceptually simple in
approach we currently lack sufficiently detailed knowledge of the
pathways in humans activated during nausea and their associated
neurotransmitters and receptors.
CONCLUSION
The key steps in the identification and development of the
current armamentarium of anti-emetic drugs reveal a number
of recurrent themes with resonance in other drug discovery
areas. These include: the use of traditional medicines as a basis
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for new drugs; the frequent role of serendipity and exploitation
of fortuitous observations; the impact of “non-research” issues
such as mergers, takeovers, management decisions, patents, and
associated litigation; the challenges of translation of animal
models to the clinic in an area where there is no single target
organ or molecular mechanism; the advances in pharmacology
which change the binding profile and nature of receptor
interactions of a drug (even after licensing); the repurposing
of drugs active at multiple receptors for one indication but
shown subsequently to exert an unanticipated profile of activity
in another indication.
The last 30 years since the discovery of 5-HT3 and NK1
receptor antagonists has seen a major advance in the treatment
of nausea and vomiting but major gaps remain including: (a)
our understanding of nausea is poor in comparison to pain
although it is arguably as common and debilitating, (b) the
relationships between appetite, disordered gastric motility and
nausea are still not understood, leading to a lack of advances in
the treatment of common disorders such as gastroparesis and
functional dyspepsia, and (c) there is no registered treatment
specifically for nausea irrespective of cause or a “universal anti-
emetic,” a drug which would block both nausea and vomiting
completely irrespective of the cause (Andrews and Sanger, 2014).
It is notable that the two major breakthroughs (involvement
of 5-HT3 and NK1 receptors) in anti-emetics occurred within
<10 years of each other and in the subsequent >20 years
there has not been a comparable “major breakthrough;” why
is this the case when molecular pharmacology has exploded
over the same period? To some extent this can be explained
by the success of the 5-HT3 and NK1 receptor antagonists
in treatment of vomiting, but the same cannot be said for
nausea, particularly in conditions such as gastroparesis. We
might ask “where will serendipity now occur in an age when
the mechanisms of action of drugs are much better understood?”
Perhaps an answer can be found in studies looking for single-
nucleotide polymorphisms associated with particular patient-
symptom associations (e.g., sensitivity to motion sickness; see
above).
A comment at a meeting to discuss anti-emetic agents for
chemotherapy is pertinent to close: “I believe it is an interesting
phenomenon that every 30 years everything done in the past
is lost” (Dr. Lassner, p21S, in Penta et al., 1981); perhaps the
answer to the question we posed about “where will new anti-
emetics come from?” is already there in the recent history of this
area.
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